-
1
-
-
33746904664
-
Clinical practice guidelines in oncology: Non-Hodgkin's lymphoma
-
National Comprehensive Cancer Network [Web site]. Available at: Accessed June 29
-
National Comprehensive Cancer Network [Web site]. Clinical practice guidelines in oncology: non-Hodgkin's lymphoma. Available at: www.nccn.org. Accessed June 29, 2006.
-
(2006)
-
-
-
2
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
3
-
-
0017132731
-
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
-
McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-1493.
-
(1976)
Cancer
, vol.38
, pp. 1484-1493
-
-
McKelvey, E.M.1
Gottlieb, J.A.2
Wilson, H.E.3
-
4
-
-
0032951328
-
International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury
-
Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17:423-429.
-
(1999)
J Clin Oncol
, vol.17
, pp. 423-429
-
-
Shipp, M.A.1
Abeloff, M.D.2
Antman, K.H.3
-
5
-
-
0023818185
-
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
-
Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-122.
-
(1988)
Blood
, vol.71
, pp. 117-122
-
-
Velasquez, W.S.1
Cabanillas, F.2
Salvador, P.3
-
6
-
-
0028261089
-
ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
-
Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-1176.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1169-1176
-
-
Velasquez, W.S.1
McLaughlin, P.2
Tucker, S.3
-
7
-
-
0032761285
-
Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
-
Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776-3785.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3776-3785
-
-
Moskowitz, C.H.1
Bertino, J.R.2
Glassman, J.R.3
-
8
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
-
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
-
(1995)
N Engl J Med
, vol.333
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
-
9
-
-
0002421959
-
CHOP is curative in 30% of patients with large cell lymphoma: A twelve-year Southwest Oncology Group follow-up
-
In: Skarin AT, ed. New York, NY: Park Row
-
Coltman C, Dahlberg S, Jones SE, et al. CHOP is curative in 30% of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin AT, ed. Advances in Cancer Chemotherapy. New York, NY: Park Row; 1986:71-78.
-
(1986)
Advances in Cancer Chemotherapy
, pp. 71-78
-
-
Coltman, C.1
Dahlberg, S.2
Jones, S.E.3
-
10
-
-
0036234795
-
A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma
-
Webb MS, Saltman DL, Connors JM, et al. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43:975-982.
-
(2002)
Leuk Lymphoma
, vol.43
, pp. 975-982
-
-
Webb, M.S.1
Saltman, D.L.2
Connors, J.M.3
-
11
-
-
0032784782
-
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
-
Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3786-3792.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3786-3792
-
-
Fossa, A.1
Santoro, A.2
Hiddemann, W.3
-
12
-
-
0032936294
-
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory /recurrent non-Hodgkin's lymphoma patients
-
Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10:351-354.
-
(1999)
Ann Oncol
, vol.10
, pp. 351-354
-
-
Germann, N.1
Brienza, S.2
Rotarski, M.3
-
13
-
-
0025906889
-
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease
-
Silver RT, Case DC Jr, Wheeler RH, et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9:754-761.
-
(1991)
J Clin Oncol
, vol.9
, pp. 754-761
-
-
Silver, R.T.1
Case Jr., D.C.2
Wheeler, R.H.3
-
14
-
-
0029121860
-
Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives
-
De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995; 48:30-38.
-
(1995)
Mol Pharmacol
, vol.48
, pp. 30-38
-
-
De Isabella, P.1
Palumbo, M.2
Sissi, C.3
-
15
-
-
0035746666
-
BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity
-
Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001; 87:407-416.
-
(2001)
Tumori
, vol.87
, pp. 407-416
-
-
Beggiolin, G.1
Crippa, L.2
Menta, E.3
-
16
-
-
0034988022
-
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
-
Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12:661-667.
-
(2001)
Ann Oncol
, vol.12
, pp. 661-667
-
-
Borchmann, P.1
Schnell, R.2
Knippertz, R.3
-
17
-
-
0141649441
-
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
-
Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003; 88:888-894.
-
(2003)
Haematologica
, vol.88
, pp. 888-894
-
-
Borchmann, P.1
Morschhauser, F.2
Parry, A.3
|